Improving patient outcomes in leukaemia by targeting cancer stem cells [ 2014 - 2018 ]

Research Grant

Researchers: A/Pr Steven Lane (Principal investigator)

Brief description Blood cancers such as acute myeloid leukaemia (AML) are among the most deadly types of cancer and new treatments are desperately needed to improve patient’s survival in these diseases. AML cancer-causing stem cells survive by turning on immortalization programs and we hope to specifically kill these AML stem cells by blocking these crucial pathways. This includes things that control the way the cells divide and the way they respond to genetic damage as well as other novel pathways.

Funding Amount $AUD 294,763.13

Funding Scheme Career Development Fellowships

Notes Clinical CDF